African Population and Children as Guinea-Pigs for Pentagon, Metabiota (Bidens) & Gates Experiments on Virus, Vaccines
Introduction by Gospa News Editorial Staff
This is the collage of four different articles on experiments which targeted African population and children too to discover dangerous lethal virus and test news vaccines.
The people were used as guinea-pigs by Pentagon and Metabiota (American company tied with Bidens), according to Russian experts on bacteriological research, but also by the notorious Bill gates.
Russian top brass: Pentagon wanted to test unregistered medicines on African population
The Pentagon planned to use its biolaboratories in Africa to test unregistered medicines on the local population, Chief of Russia’s Radiation, Chemical and Biological Protection Troops Lieutenant General Igor Kirillov said on Tuesday.
According to Kirillov, documents that were found in Ukraine indicate that the Pentagon planned to use the US army to test unregistered medical drugs on the local population and then submit them for approval by supervisory authorities “in the interests of the so-called big pharma.” For these ends, it was planned to use its biolaboratories and facilitating agencies, such as Metabiota.
“Take note of Metabiota’s commercial offer marked ‘confidential,’ which was found among documents at one of the biolaboratories in Ukraine. The offer is addressed to the United States Army Medical Research Institute of Infectious Diseases and concerns training of specialists in infectious diseases in Kenya and Uganda.
The document demonstrates that the Defense Threat Reduction Agency’s (DTRA) and the Department of Homeland Security were involved in the study of pathogens in African countries, while the US Agency for International Development and a number of European Union structures were engaged to make these activities look like ‘humanitarian cooperation,’” he said at a briefing on the analysis of documents concerning the United States’ military biological activities.
Apart from that, in his words, evidence was found showing that Metabiota had been involved in the study of the H7N9 bird flu virus and that it had played a leading role in the implementation of the Predict project for the study of new coronavirus types, under which their carriers – bats – had been caught.
“We have repeatedly pointed to the company’s ties with the son of the US incumbent president, Hunter Biden, and government organizations. Notably, Metabiota’s representatives admit that as a matter of fact they are establishing ties to ensure the Pentagon and other American agencies’ work abroad,” Kirillov added.
Originally published by TASS Russia News Agency
Russia has evidence of Metabiota’s work in Africa in US government’s interests
The documents obtained in the special military operation in Ukraine testify to the work of the US company Metabiota in Africa in the interests of US government agencies, including the Department of State, Chief of Russia’s Radiation, Chemical and Biological Protection Troops Lieutenant-General Igor Kirillov said on Monday.
“The documents obtained in the special military operation confirm the link between the Walter Reed Institute and the US Defense Threat Reduction Agency (DTRA) and its key contractor, the company Metabiota. The available financial and scientific documents testify to the company’s activity on the territory of Africa – in Kenya, Uganda and South Africa. In addition to the US Defense Threat Reduction Agency (DTRA), the documents list the US National Security Agency and Department of State among customers represented by the US government,” the general said.
The documents describe Metabiota’s ‘flexible’ methods of activity making it possible to cover up the US government’s participation in foreign projects and resolve bureaucratic issues through the hire of local officials. However, in the face of the international community’s growing concern, the Pentagon is forced to change its tactics in organizing ‘dual-purpose’ work, Kirillov said.
The chief of Russia’s Radiation, Chemical and Biological Protection Troops also pointed to the existence of a ramified network of branches of the US Walter Reed Army Institute of Research and the US Naval Medical Research Command. The Walter Reed Institute has four overseas branches furnished with laboratories featuring a high level of biological isolation and a network of regional units for sample selection and strain transportation, he said.
“The scale of ongoing work with dangerous pathogens can be evidenced by about 500 staff of the branch located in Thailand. The branch has units in Nepal, Cambodia and the Philippines, which, in turn, interact with 12 more Southeast Asian countries,” Kirillov said.
“Apart from the US Army Research Institute, the US Naval Medical Research Command also has a network of foreign branches. Its NAMRU subordinate laboratories carry out work with pathogenic microorganisms in North Africa, the Middle East and South America.
Such a ‘ramified’ approach implemented throughout the world allows the US defense agency to gain access to epidemically significant pathogen variants that are potential biological weapon agents. They include the Marburg and Ebola fevers, malaria and the Rift Valley fever,” the chief of Russia’s Radiation, Chemical and Biological Protection Troops said.
Originally published by TASS Russian News Agency
Trial of Gates-Funded Vaccine Patch for Infants in Gambia
Micron Biomedical tested microneedle-based delivery of the measles-rubella (MR) vaccine on children in Gambia with backing from the Bill & Melinda Gates Foundation and the Centers for Disease Control and Prevention (CDC).
Microarray injections are administered via a microneedle patch that looks like a Band-Aid and is applied by pressing it to the skin. Once applied, microneedles penetrate the upper layer of the skin to deliver the vaccine.
The study, which researchers presented last week at the Microneedles 2023 conference in Seattle, evaluated the safety, immunogenicity and acceptability of the leading commercially available MR vaccine from the Serum Institute of India delivered by Micron’s microarray technology in adults, toddlers and infants.
Proponents of this vaccination method, such as Gavi, the Vaccine Alliance — of which the Gates Foundation is a founding member — call the patches “the future of vaccination, where these lifesaving interventions are delivered painlessly, without the need for syringes or perhaps even trained medical professionals.”
“Supporting innovations in vaccine delivery is critical to addressing ongoing health inequities,” James Goodson, co-investigator for the study and senior scientist and epidemiologist at the CDC’s Global Immunization Division, said in the press release.
He added that the study also is a key step toward getting the patches licensed. Developers tout the technology as painless — it feels like Velcro, they claim — and more thermostable than traditional vaccines.
This would make widespread global distribution of the vaccines easier, they said, particularly in developing areas that may lack infrastructure, such as refrigeration, and trained professionals.
Extract by The Defender – read whole article here
Gates Commits $400 Million to Test New TB Vaccine on 26,000 People in Africa and Southeast Asia
The Bill & Melinda Gates Foundation and Wellcome Trust on Wednesday announced plans to fund a phase 3 clinical trial for a tuberculosis (TB) vaccine that will be tested on 26,000 people at 50 sites in Africa and Southeast Asia over the next four to six years.
Gates committed $400 million to the trial and Wellcome — the largest funder of medical research in the U.K. and one of the largest in the world — committed an additional $150 million. The trials will test the M72/AS01 vaccine, developed by pharmaceutical giant GSK (formerly GlaxoSmithKline) with partial funding from the Gates Foundation.
“I’m concerned that they’re planning on conducting the trial in underdeveloped nations,” Hooker said. “It seems almost prototypical that the underserved have to be guinea pigs for the rest of the world.”
He added, “Fifty percent is incredibly low efficacy for such an ‘important’ intervention to go to essentially everyone in the developing world.”
TB more common among poor
GSK developed the vaccine and ran smaller, “proof-of-concept” phase 2b trials on it in 2018, reporting a 54% efficacy rate. But the vaccine maker didn’t move forward with the large-scale trials needed for a license.
Instead, it passed the license to the Gates Medical Research Institute, a nonprofit biotech spinoff of the Gates Foundation dedicated to developing “novel biomedical interventions” to treat global health problems.
The existing vaccine for TB, the BCG (bacille Calmette-Guérin) vaccine, was developed in 1921 and is effective at stopping TB infection among children but has limited efficacy in adults.
Recent estimates suggest up to 25% of the global population carries a latent (asymptomatic) TB infection, which may later become active among 5-15% of latent carriers. People with latent infection cannot spread the disease.
TB kills 1.6 million people per year, primarily in low and middle-income countries. It is treatable and curable with antibiotics. Drug-resistant strains have emerged, but those also are treatable and curable using second-line drugs.
TB is more common among poor people, who are more likely to work in poorly ventilated and overcrowded conditions, suffer from malnutrition and have more limited access to healthcare.
The funded trial will test whether the experimental vaccine can prevent adolescents and adults with latent tuberculosis from developing symptoms.
Extract by The Defender – read whole article here
LINKS MAIN SOURCES